Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Left ventricular ejection fraction \<45%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan within 18 months~* On stable chronic guideline-directed therapy for HF including chronic loop diuretics, ACEi, ARBs, MRAs, ARNI or / and β-blockers as tolerated, with no changes of these medications in the past 2 weeks~* At least an oral dose of 40 mg of furosemide/day or equivalent (20 mg torsemide, 1 mg bumetamide)~Exclusion Criteria:~* SBP \< 115 mm Hg or \> 180 mm Hg at screening or pre-randomization~* Heart rate \< 50 beats per minute (bpm) or \> 120 bpm at screening or pre-randomization~* Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic or uncorrected severe valvular disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo+Diuretic to BMS-986231+Diuretic (Type: EXPERIMENTAL): Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
- BMS-986231+Diuretic to Placebo+Diuretic (Type: EXPERIMENTAL): Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods

Based on this trial design, predict the completion outcome and termination type (if applicable).